Dogwood Therapeutics Stock (NASDAQ:DWTX)

Financials Chart

Previous Close

$3.00

52W Range

$1.62 - $29.28

50D Avg

$6.15

200D Avg

$4.98

Market Cap

$7.95M

Avg Vol (3M)

$3.96M

Beta

2.01

Div Yield

-

DWTX Company Profile

Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

12

IPO Date

-

Website

DWTX Performance

DWTX Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	-	-
Operating Income	$-12.23M	$-5.45M	$-12.32M
Net Income	$-12.35M	$-5.30M	$-12.25M
EBITDA	$-12.25M	$-5.45M	$-12.32M
Basic EPS	-	$-7.05	$-27.75
Diluted EPS	-	$-7.05	$-27.75

Fiscal year ends in Dec 24 | Currency in USD